Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

Annovis faces financial challenges and questionable efficacy in Alzheimer's and Parkinson's trials, risking poor stock ...

Potomac-based IGC Pharma Inc. Thursday announced enrollment of patients at the Baycrest Academy for Research and Education in ...

Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain ...

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...

One of the raw materials studied by the group is cashew nut shell liquid, a by-product of oilseed processing; work was ...

Alzheimer's disease might damage the brain in two distinct phases, a new study suggests. An early phase that occurs slowly ...

Nexalin Technology's clinical trial results highlight notable cognitive improvements in Alzheimer's patients using Deep Intracranial Frequency Stimulation technology. The study showed significant ...

A recent study suggests that a drug approved for the treatment of seizures may also help treat Alzheimer's in people who do ...

Researchers from Yale-NUS College have made a significant discovery that could change how we understand Alzheimer’s disease, ...

Fruit flies aiding in research for Sanfilippo syndrome treatment. Researchers at Clemson University study enzyme defects and ...

Alzheimer's disease may damage the brain in two distinct phases, based on new research funded by the National Institutes of Health (NIH) using sophisticated brain mapping tools.